Nusartan Tablet 80 mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
Austin Pharmaceuticals Co., Ltd.
MFDS item code 201208468 · Approved 2012.11.19
This product's status changed to Expired on 2024.07.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension and heart failure, and reduction of the risk of death following myocardial infarction
This medication is used to treat essential hypertension, heart failure (especially when ACE inhibitors cannot be used), and to reduce the risk of death after myocardial infarction. The main indications include improving hypertension by controlling blood pressure, alleviating symptoms of heart failure, and reducing the mortality risk in patients with impaired left ventricular function after myocardial infarction. Appropriate doses should be chosen based on the patient's condition for treatment.
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg per day. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily and do not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily, and it may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, followed over several weeks by dose increases, according to patient tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is necessary if creatinine clearance is 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine to these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
1) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. People allergic to this medication or its components, pregnant or potentially pregnant women, and nursing mothers should not take this medication. Patients with severe liver dysfunction, severely impaired kidney function, or hereditary angioedema should also avoid this medication. Caution is needed for elderly patients, patients with hyperkalemia or those with easily rising serum potassium levels, and patients with mild to moderate liver impairment when taking this medication. Patients with heart failure, those after myocardial infarction, or pre-operative patients should closely monitor kidney function and blood pressure when taking this medication. When starting this medication, blood pressure may drop sharply, leading to dizziness or fainting, so particularly for patients undergoing dialysis or taking diuretics, it should be initiated at a low dose and gradually increased. This medication may cause potassium levels to rise dangerously when taken with potassium-sparing diuretics or potassium supplements. Caution is also needed when taken with non-steroidal anti-inflammatory drugs (NSAIDs) as it may diminish the blood pressure-lowering effect and worsen kidney function. When used with lithium preparations, lithium levels may increase, leading to toxicity, so monitoring serum levels is necessary. This medication may cause dizziness or drowsiness when driving or operating machinery, so caution is advised. In case of overdose, severe hypotension, reduced consciousness, and shock can occur, and immediate medical assistance is required. Safety and efficacy in children and adolescents have not been established, so use should be avoided. This medication should be kept out of reach of children, and transferring it to other containers may compromise its quality.
Headache
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture and kept in a cool place below 30 degrees Celsius, away from direct sunlight or high temperatures.
Pink round film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Valsartan 80mg
Tablet · Prescription medication
Austin Pharmaceuticals Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.